Navigation Links
European Urology: Editorial about REDUCE trial underlines value of dutasteride
Date:5/25/2010

Arnhem -- On 8 May an editorial about the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial by Fritz H. Schrder and Monique J. Roobol was published in the online version of European Urology, the scientific journal of the European Association of Urology (EAU).

The long-expected final report of the REDUCE trial appeared on April 1, 2010 in the New England Journal of Medicine [1] together with a commentary entitled 'Chemoprevention of prostate cancer' by Dr Patrick Walsh. What were the noteworthy items of the editorial?

  • The REDUCE trial, contrary to the Prostate Cancer Prevention Trial (PCPT) [2], is performed in men who would have been candidates for biopsy anyway because of PSA values of 2.5 10 ng/ml, making the reduction of the chance of a positive biopsy of 23% clinically relevant.

  • The mechanism of dutasteride is not primarily prevention but the inhibition of growth of small, well differentiated cancers as a result of the intracellular reduction of 5a-dihydrotestosterone (DHT). This mechanism which results in the prevention of disease progression is called 'tertiary prevention' and in this setting can be seen as treatment of minimal disease. This effect is seen in spite of the simultaneous, up to 40 times increase in testosterone (T) [3]. It remains unclear why the rise in T does not prevent the effect of the reduction in DHT.

  • The report indicates a small difference in cardiovascular side effects in disadvantage of dutasteride. The long-term general health effects obviously remain unknown at this time.

  • Unanswered issues: is dutasteride useful in reducing unnecessary biopsies and does it help to selectively identify aggressive disease? The reported data show that in men with an indication of periodic biopsies the reduction in the detection of potentially over-diagnosed cancers is 28.2% (table 3 in [1]).

  • More detailed analyses are warranted. Extended follow-up to monitor, for example, the outcome of relevant endpoints such as delayed diagnosis of aggressive cancers, progression to metastatic disease and disease-specific mortality in comparison to the control population will be of great scientific value in spite of the unblinding of the trial and should therefore have top priority.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. European Cancer Organization supports a revision of the EU Clinical Trials Directive
2. Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
3. Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)
4. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
5. The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center
6. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
7. Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems
8. Lower detection of prostate cancer with PSA screening in US than in a European randomized trial
9. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
10. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
11. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Based on ... safety and efficacy of HBOT in treating and helping to heal addictions and ... research showing the similarities of the wounds to the brain from traumatic brain ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... healthcare industry, made the 2017 Inc. 5000 with a three-year sales growth ... nation’s fastest-growing private companies and comprises the most comprehensive look at America’s independent ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... the American Academy of Orthopaedic Surgeons , points out that therapeutic modalities ... from pain or injury. According to the report, a wider scope of physical ...
(Date:8/22/2017)... ... August 22, 2017 , ... The old adage ... as simple as eating healthy foods. But this well-known piece of nutrition advice ... or breaking apart carbohydrates—depends not only on properties of the food but also ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
Breaking Medicine Technology: